Capital Costs to report. There are no Operating or Maintenance Costs to report.

**REQUESTS FOR COMMENTS: Written** comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility and clarity of the information to be collected: and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Charles R. MacKay, Project Clearance Officer, Office of Policy for Extramural Research Administration, Office of Extramural Research, Office of the Director, NIH, Rockledge 2, 6701 Rockledge Drive, MSC 7730, Room 2196, Bethesda, MD 20892–7730, or call nontoll-free number (301) 435–0978 or E-mail your request, including your address to: cm13f@nih.gov.

**COMMENTS DUE DATE:** Comments regarding this information collection are best assured of having their full effect if received on or before December 9, 1996.

Dated: October 3, 1996.

Geoffrey E. Grant,

Acting Deputy Director for Extramural Research, NIH.

[FR Doc. 96–25978 Filed 10–9–96; 8:45 am] BILLING CODE 4140–01–M

### Notice of a Meeting of the Office of AIDS Research Advisory Council

Pursuant to P.L. 92–463, notice is hereby given of the Third meeting of the Office of AIDS Research Advisory Council (OARAC) on October 29, 1996, from 8:30 a.m. to 5:00 p.m., at the National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, Sixth Floor, Conference Room 10. The meeting will be open to the public.

The Office of AIDS Research is responsible for the planning, coordination, and evaluation of the NIH AIDS research program. The OARAC was established to advise the Director of the OAR regarding these activities.

The agenda of the meeting will include the following: the FY 1997 AIDS research budget, the FY 1998 HIH Plan for HIV-Related Research, the process for implementing the recommendations from the NIH AIDS Research Program Evaluation, and a new proposal for the use of the OAR discretionary fund.

Copies of the meeting agenda and the roster of council members will be furnished upon request by Jeannette R. De Lawter, Program Analyst, Office of AIDS Research, National Institutes of Health, Building 31, Room 4B54,9000 Rockville Pike, Bethesda, MD 20892, Phone (301) 402–3357, Fax (301) 402–3360. Any individual who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. De Lawter no later than October 22.

Dated: October 3, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25970 Filed 10–9–96; 8:45 am] BILLING CODE 4140–01–M

### National Cancer Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C., Appendix 2), notice is hereby given of the meetings of the National Cancer Institute Special Emphasis Panel (SEP):

*Name of SEP:* 3D Conformal Radiation Therapy.

Date: October 15–17, 1996.

Time: October 15—7 pm, October 16–17, 8 am.

*Place:* Dumont Hotel—New York; New York, NY 10016.

Contact Person: Dr. Gerald Lovinger, Scientific Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 630C, 6130 Executive Boulevard MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/ 496–7987.

Purpose/Agenda: This meeting will be devoted to the review, discussion, and evaluation of a grant application.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of SEP: Oncogenes & Mitogenes— Intracellular.

Date: October 22, 1996.

Time: October 22-1 pm.

*Place:* Teleconference, Executive Plaza North, 6130 Executive Boulevard, Rockville, MD 20852.

Contact Person: Dr. Martin H. Goldrosen, Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 635F, 6130 Executive Boulevard MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/496–7930.

*Purpose/Agenda:* This meeting will be devoted to the review, discussion, and evaluation of a grant application.

Name of SEP: Synthesis of Selected Chemical Carcinogens and Chemopreventive Agents.

Date: October 25, 1996. Time: October 25—8:30 am. Place: 6100 Executive Boulevard,

Conference Room 1, Rockville, MD 20852. Contact Person: Dr. Courtney Michael Kerwin, Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 601, 6130 Executive Boulevard MSC 7405, Bethesda, MD 20892–7405. Telephone: 301/496–7421.

*Purpose'Agenda:* This meeting will be devoted to the review, discussion, and evaluation of a grant application.

Name of SEP: Biology & Genetics of Marrow Allografts for Leukemia.

Date: November 20-22, 1996.

*Time:* November 20—7 pm, November 21–22, 8 am.

*Place:* Loews New York, 569 Lexington Avenue, New York, NY 10022.

Contact Person: Dr. Ray Bramhall, Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 643, 6130 Executive Boulevard MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/496–3428.

*Purpose/Agenda:* This meeting will be devoted to the review, discussion, and evaluation of a grant application.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 3, 1996.

Paula N. Hayes,

Acting Management Officer, NIH.

[FR Doc. 96-25971 Filed 10-9-96; 8:45 am]

BILLING CODE 4140-01-M

## National Cancer Institute; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given of a meeting of the President's Cancer Panel.

This meeting will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such

as sign language interpretation or other reasonable accommodations, should notify the Contract Person listed below.

This meeting will be closed in accordance with the provisions set forth in section 552b(c)(9), Title 5, U.S.C. for discussion of future meetings and preparation of the annual report of the President. These discussions could disclose information, the premature disclosure of which would be likely to significantly frustrate implementation of proposed action the Panel may plan to take.

Carole Frank, the Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630M, 6130 Executive Blvd., MSC 7405, Bethesda, MD 20892–7405 (301/496–5708) will provide a summary of the meeting and the roster of committee members upon request. Other information pertaining to the meetings may be obtained from the contact person indicated below.

Committee Name: President's Cancer Panel.

Date: October 24-25, 1996.

Place: Rhode Island Hospital, George Building, George Auditorium, 593 Eddy Street, Providence, RI 02903.

Closed: October 24, 1996—7 p.m. to 9 p.m. Agenda: Planning Session to discuss future meetings and preparation of the mandatory Annual Report of the Chairman to the President.

*Open:* October 25, 1996—8:30 a.m. to 5 p.m.

Agenda: Issues in Translational Research/ The Crisis and Solutions for Phase I Trials and Associated Issues.

Contact Person: Dr. Maureen O. Wilson, Executive Secretary, National Cancer Institute, Building 31, Room 4A43–2473, 31 Center Drive, Bethesda, MD 20892–2473, 301/496–1148.

This notice is being published less than 15 days prior to the meeting due to the urgent need to proceed with the meeting as scheduled in order to address these issues in a timely manner.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 3, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25972 Filed 10–9–96; 8:45 am] BILLING CODE 4140–01–M

#### **National Institute of Health**

### National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

Purpose/Agenda: Review, discussion and evaluation of individual grant applications. Committee Name: NCI Initial Review Group—Education Subcommittee G. Date: November 13, 1996.

Time: 8 a.m.

Place: The Holiday Inn Georgetown, 2101 Wisconsin Avenue, N.W., Washington, DC 20007.

Contact Person: Dr. John W. Abrell, Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 635B, 6130 Executive Boulevard MSC 7405, Bethesda, MD 20892–7405 Telephone: 301/496–9767.

The meeting will be closed in accordance with the provisions set forth in sections 552(c)(4) and 552b(c)(6), title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 3, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25973 Filed 10–9–96; 8:45 am] BILLING CODE 4140–01–M

#### National Institutes of Health

# National Cancer Institute; Notice of Meetings

Pursuant to Public Law 92–463, notice is hereby given of the meetings of the Board of Scientific Counselors, National Cancer Institute.

The meetings will be open to the public as indicated below, with attendance by the public limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meetings.

The meetings will be closed in accordance with the provisions set forth

in section 552b(c)(6), Title 5, U.S.C. The closed sessions will be devoted to the review, discussion and evaluation of individual programs and projects. This will include consideration of personnel qualifications and performance, the competence of individual investigators and similar matters, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Committee Name: Board of Scientific Counselors, National Cancer Institute—Clinical Sciences Subcommittee.

Date: November 4, 1996.

*Place:* National Institutes of Health, 9000 Rockville Pike, Bldg. 31, C Wing, 6th floor, Conference Room 10, Bethesda, MD 20892.

Open: November 4, 1996—8:30 a.m. to 9:00 a.m.

Agenda: Welcoming remarks, introductions and several presentations regarding the National Cancer Institute's current and future activities.

Closed: November 4, 1996—9:00 a.m. to 6:00 p.m.

Agenda: To discuss administrative confidential site visit reports pertaining to laboratories in the Division of Clinical Sciences.

Contact Person: Edison Liu, M.D., Building 31, Room 3A11, 9000 Rockville Pike, Bethesda, MD 20892, Telephone: (301) 496–3251.

Committee Name: Board of Scientific Counselors, National Cancer Institute—Basic Sciences Subcommittee.

Date: November 6-7, 1996.

*Place*: National Institutes of Health, 9000 Rockville Pike, Bldg. 31, C Wing, 6th floor, Conference Room 10, Bethesda, MD 20892.

*Open:* November 7, 1996—8:30 a.m. to 9:00 a.m.

Agenda: Welcoming remarks, introductions and several presentations regarding the National Cancer Institute's current and future activities.

Closed: November 6, 1996—7:00 p.m. to 10:00 p.m., November 7, 1996—9:00 a.m. to 6:00 p.m.

Agenda: To discuss administrative confidential site visit reports pertaining to laboratories in the Division of Basic Sciences.

Contact Person: Edward Harlow, Ph.D., Building 31, Room 3A11, 9000 Rockville Pike, Bethesda, MD 20892, Telephone: (301) 435–2277.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research manpower; 93.399, Cancer Control)

Dated: October 3, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25974 Filed 10–9–96; 8:45 am] BILLING CODE 4140–01–M